AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20528823 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol infusion
Number of subjects: 32
Study 19059570 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly self-monitoring of INR (group B)
Number of subjects: 67
Study 19059570 — intervention group
Group type: COMPARATOR
Intervention: Monthly laboratory monitoring (group A)
Number of subjects: 67
Study 16629781 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 microg once daily
Number of subjects: 17
Study 16629781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 12860365 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular olanzapine (2.5-10 mg/injection)
Number of subjects: 1251
Study 12860365 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular placebo
Number of subjects: 1251
Study 12860365 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular haloperidol (7.5 mg/injection)
Number of subjects: 1251
Study 12860365 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular olanzapine
Number of subjects: 1251
Study 11028256 — intervention group
Group type: EXPERIMENTAL
Intervention: terazosin 1, 2, and 5 mg
Number of subjects: 128
Study 11028256 — intervention group
Group type: EXPERIMENTAL
Intervention: terazosin 2, 5, and 10 mg
Number of subjects: 128
Study 11028256 — intervention group
Group type: EXPERIMENTAL
Intervention: terazosin 20, 40, and 80 mg
Number of subjects: 128
Study 11028256 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 128
Study 9365347 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbow antagonists reversal exercise
Number of subjects: 28
Study 9365347 — intervention group
Group type: COMPARATOR
Intervention: Elbow extension only resistance exercise (control)
Number of subjects: 28
Study 9365347 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 28
Study 1550967 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% amorolfine cream
Number of subjects: 75
Study 1550967 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% amorolfine cream
Number of subjects: 75
Study 1550967 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% amorolfine cream
Number of subjects: 75
Study 1550967 — intervention group
Group type: COMPARATOR
Intervention: 1% bifonazole cream
Number of subjects: 75
Study 2951798 — intervention group
Group type: EXPERIMENTAL
Intervention: Duovent (fenoterol 100 micrograms and ipratropium bromide 40 micrograms)
Number of subjects: 16
Study 2951798 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 16
Study 2951798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29351487 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 15
Study 29351487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 29351487 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine with atropine
Number of subjects: 15
Study 29351487 — intervention group
Group type: COMPARATOR
Intervention: Placebo with atropine
Number of subjects: 15
Study 25896101 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS + A (endotoxemia with amino acid supplementation)
Number of subjects: 8
Study 25896101 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS (endotoxemia)
Number of subjects: 8
Study 25896101 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal conditions)
Number of subjects: 8
Study 25247817 — intervention group
Group type: EXPERIMENTAL
Intervention: Low offers by a proposer
Number of subjects: 0
Study 22419860 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside 1000 (100 mg)
Number of subjects: 12
Study 22419860 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside 1000 (200 mg)
Number of subjects: 12
Study 19032373 — intervention group
Group type: EXPERIMENTAL
Intervention: CoaguChek S or XS POC meter during the PST arm
Number of subjects: 151
Study 19032373 — intervention group
Group type: COMPARATOR
Intervention: Routine care by the anticoagulation management service
Number of subjects: 151
Study 18070440 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM)
Number of subjects: 57
Study 18070440 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ADM)
Number of subjects: 57
Study 16075412 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisotec (Julphar, UAE)
Number of subjects: 28
Study 16075412 — intervention group
Group type: COMPARATOR
Intervention: Zestril (AstraZeneca, UK)
Number of subjects: 28
Study 10925438 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite cement
Number of subjects: 40
Study 10925438 — intervention group
Group type: COMPARATOR
Intervention: Methyl methacrylate implants
Number of subjects: 40
Study 9313020 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 162
Study 9313020 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Clonidine and Naltrexone
Number of subjects: 162
Study 9313020 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 162
Study 8117550 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 6435
Study 8117550 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 6435
Study 3086991 — intervention group
Group type: EXPERIMENTAL
Intervention: Second first-day endocervical culture
Number of subjects: 748
Study 3086991 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-day cultures
Number of subjects: 748
Study 3086991 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal cultures
Number of subjects: 748
Study 30075711 — intervention group
Group type: EXPERIMENTAL
Intervention: IRIS intervention (Identification and Referral to Improve Safety) implemented in general practices; details on dosage and duration not specified.
Number of subjects: 201
Study 30075711 — intervention group
Group type: COMPARATOR
Intervention: Comparator borough (not specified in detail); control group for segmented regression analysis.
Number of subjects: 201
Study 27382535 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% CHX gluconate mouthwash
Number of subjects: 45
Study 27382535 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% H2O2 mouthwash
Number of subjects: 45
Study 27382535 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planning (SRP) only
Number of subjects: 45
Study 23171414 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep restriction group (4 hours of sleep for 5 nights, then restored to 8 hours for 2 nights)
Number of subjects: 20
Study 23171414 — intervention group
Group type: COMPARATOR
Intervention: Control group (8 hours of sleep each night)
Number of subjects: 20
Study 21247538 — intervention group
Group type: EXPERIMENTAL
Intervention: XIENCE V everolimus‐eluting stent (EES)
Number of subjects: 1002
Study 17934527 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized PC-supported training
Number of subjects: 157
Study 17934527 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological group therapy
Number of subjects: 157
Study 17934527 — intervention group
Group type: COMPARATOR
Intervention: No specific training (Control group)
Number of subjects: 157
Study 16516083 — intervention group
Group type: EXPERIMENTAL
Intervention: rHDL containing low- or high-dose AIM
Number of subjects: 47
Study 16516083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 12663588 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (50 ml MgCl(2) solution daily for 16 weeks)
Number of subjects: 63
Study 12663588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 11149501 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamed intramedullary nailing
Number of subjects: 48
Study 11149501 — intervention group
Group type: COMPARATOR
Intervention: Unreamed intramedullary nailing
Number of subjects: 48
Study 9315990 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam 0.5 mg
Number of subjects: 413
Study 9315990 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam 1.0 mg
Number of subjects: 413
Study 9315990 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam 2.0 mg
Number of subjects: 413
Study 9315990 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam 3.0 mg
Number of subjects: 413
Study 9315990 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam 4.0 mg
Number of subjects: 413
Study 9315990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 413
Study 8225672 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed recanalisation of the infarct related artery
Number of subjects: 23
Study 8225672 — intervention group
Group type: COMPARATOR
Intervention: Immediate recanalisation of the infarct related artery
Number of subjects: 23
Study 8225672 — intervention group
Group type: COMPARATOR
Intervention: Unsuccessful thrombolysis (Group 3)
Number of subjects: 23
Study 3501763 — intervention group
Group type: EXPERIMENTAL
Intervention: tertatolol 5 mg
Number of subjects: 12
Study 3501763 — intervention group
Group type: COMPARATOR
Intervention: propranolol 80 mg
Number of subjects: 12
Study 3501763 — intervention group
Group type: COMPARATOR
Intervention: atenolol 100 mg
Number of subjects: 12
Study 3501763 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 29778387 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal antidepressant use (n = 90)
Number of subjects: 3258
Study 29778387 — intervention group
Group type: EXPERIMENTAL
Intervention: Currently active major depression (MD) in female partners
Number of subjects: 3258
Study 29778387 — intervention group
Group type: EXPERIMENTAL
Intervention: Currently active MD in male partners
Number of subjects: 3258
Study 27234658 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol 5mg
Number of subjects: 12
Study 27234658 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol 10mg
Number of subjects: 12
Study 27234658 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol 20mg
Number of subjects: 12
Study 27234658 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol 30mg
Number of subjects: 12
Study 27234658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 27234658 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 30mg
Number of subjects: 12
Study 27234658 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 60mg
Number of subjects: 12
Study 24671634 — intervention group
Group type: EXPERIMENTAL
Intervention: Curved direct contact interface (Group 1)
Number of subjects: 200
Study 24671634 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified interface with SoftFit™ (Group 2)
Number of subjects: 200
Study 23378299 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild renal dysfunction
Number of subjects: 4757
Study 23378299 — intervention group
Group type: EXPERIMENTAL
Intervention: Low high-density lipoprotein cholesterol and insulin resistance phenotype
Number of subjects: 4757
Study 19801149 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (20 mg)
Number of subjects: 190
Study 19801149 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Pravastatin (20 mg)
Number of subjects: 190
Study 19801149 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-therapy with Pravastatin
Number of subjects: 190
Study 18507667 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group 1 (conventional drill preparation with immediate functional loading)
Number of subjects: 151
Study 18507667 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group 2 (osteotome technique with immediate functional loading)
Number of subjects: 151
Study 18507667 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard preparation procedure with submerged healing)
Number of subjects: 151
Study 18507667 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group 1
Number of subjects: 151
Study 18507667 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group 2
Number of subjects: 151
Study 18507667 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 151
Study 20546215 — intervention group
Group type: EXPERIMENTAL
Intervention: ingenol mebutate gel, 0.05% (Arm A)
Number of subjects: 60
Study 20546215 — intervention group
Group type: EXPERIMENTAL
Intervention: ingenol mebutate gel, 0.0025% or 0.01% (Arm A)
Number of subjects: 60
Study 20546215 — intervention group
Group type: COMPARATOR
Intervention: vehicle gel (Arm A and B)
Number of subjects: 60
Study 20546215 — intervention group
Group type: EXPERIMENTAL
Intervention: ingenol mebutate gel (Arm A)
Number of subjects: 60
Study 16218171 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN monotherapy (9 MU IFN‐alpha2a three times weekly)
Number of subjects: 31
Study 16218171 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN plus RBV (1000‐1200 mg/day)
Number of subjects: 31
Study 12377318 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 Gy
Number of subjects: 168
Study 12377318 — intervention group
Group type: EXPERIMENTAL
Intervention: 78 Gy
Number of subjects: 168
Study 12377318 — intervention group
Group type: COMPARATOR
Intervention: Biopsy negative
Number of subjects: 168
Study 12377318 — intervention group
Group type: COMPARATOR
Intervention: Biopsy positive
Number of subjects: 168
Study 9926800 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymerized hemoglobin
Number of subjects: 0
Study 9926800 — intervention group
Group type: COMPARATOR
Intervention: Banked blood
Number of subjects: 0
Study 7821476 — intervention group
Group type: EXPERIMENTAL
Intervention: Operating microscope illumination during cataract surgery
Number of subjects: 36
Study 7821476 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cataract surgery)
Number of subjects: 36
Study 3283172 — intervention group
Group type: EXPERIMENTAL
Intervention: Education with relaxation training
Number of subjects: 30
Study 3283172 — intervention group
Group type: EXPERIMENTAL
Intervention: Education
Number of subjects: 30
Study 3283172 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 30
Study 29731412 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported Discharge Service (SDS)
Number of subjects: 0
Study 29731412 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 0
Study 26918700 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled limited formula (10 ml formula by syringe after each breastfeeding, discontinued at onset of lactation)
Number of subjects: 104
Study 26918700 — intervention group
Group type: COMPARATOR
Intervention: Standard approach (SA)
Number of subjects: 104
Study 24202399 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypokalemia interventions administered pre-admission and post-operative
Number of subjects: 118
Study 24202399 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hypokalemia interventions)
Number of subjects: 118
Study 22045607 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback device (Real CPR Help®)
Number of subjects: 15
Study 22045607 — intervention group
Group type: COMPARATOR
Intervention: Manikin (Resusci Anne® Advanced SkillTrainer)
Number of subjects: 15
Study 20693353 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (150 mg daily titrated to 300 mg daily after 3 months) added to 100 mg losartan
Number of subjects: 599
Study 20693353 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren added to losartan
Number of subjects: 599
Study 20693353 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to 100 mg losartan
Number of subjects: 599
Study 18797706 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (6‐12 min cardiovascular activity, 5‐10 min stretching, 15‐30 min resistance training, 8 min cool-down)
Number of subjects: 20
Study 18797706 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 20
Study 18797706 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 20
Study 18797706 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 16904417 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA‐SC 104 (104 mg/0.65 ml subcutaneous injection)
Number of subjects: 2053
Study 16904417 — intervention group
Group type: COMPARATOR
Intervention: DMPA‐IM (intramuscular injection)
Number of subjects: 2053
Study 12534404 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib (120 mg once daily)
Number of subjects: 742
Study 12534404 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (800 mg t.d.s.)
Number of subjects: 742
Study 12534404 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg b.d.)
Number of subjects: 742
Study 12534404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 742
Study 10491346 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (100 mg)
Number of subjects: 10
Study 10491346 — intervention group
Group type: COMPARATOR
Intervention: Nabumetone (1 g)
Number of subjects: 10
Study 10491346 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 10
Study 8902473 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 micrograms salmeterol
Number of subjects: 12
Study 8902473 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms salmeterol
Number of subjects: 12
Study 8902473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1865943 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive zinc oxide tape
Number of subjects: 38
Study 1865943 — intervention group
Group type: COMPARATOR
Intervention: Povidone iodine (10%)
Number of subjects: 38
Study 1865943 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive zinc oxide tape (high activity level)
Number of subjects: 38
Study 1865943 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive zinc oxide tape (low activity level)
Number of subjects: 38
Study 1865943 — intervention group
Group type: COMPARATOR
Intervention: Povidone iodine (10%) (high activity level)
Number of subjects: 38
Study 1865943 — intervention group
Group type: COMPARATOR
Intervention: Povidone iodine (10%) (low activity level)
Number of subjects: 38
Study 7049706 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide (2.5 mg daily)
Number of subjects: 16
Study 7049706 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (10 mg daily)
Number of subjects: 16
Study 7049706 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide plus Pindolol
Number of subjects: 16
Study 7049706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7049706 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide
Number of subjects: 16
Study 29596040 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic agents after I&D
Number of subjects: 165
Study 29596040 — intervention group
Group type: COMPARATOR
Intervention: Placebo after I&D
Number of subjects: 165
Study 26956032 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth based dietary intervention
Number of subjects: 0
Study 26956032 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 24368224 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg
Number of subjects: 280
Study 24368224 — intervention group
Group type: COMPARATOR
Intervention: Emtricitabine (FTC) 200 mg + Tenofovir disoproxil fumarate (TDF) 300 mg
Number of subjects: 280
Study 22327492 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine (Cervarix)
Number of subjects: 1113
Study 21200097 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin 5,000 U/kg
Number of subjects: 80
Study 21200097 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin 10,000 U/kg
Number of subjects: 80
Study 21200097 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin 20,000 U/kg
Number of subjects: 80
Study 21200097 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 80
Study 18772704 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose bifrontal ECT (BF)
Number of subjects: 28
Study 18772704 — intervention group
Group type: COMPARATOR
Intervention: Low-dose bitemporal ECT (BT)
Number of subjects: 28
Study 16319545 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-lasting multifactorial continued educational and behavioural programme (intensive approach)
Number of subjects: 3241
Study 16319545 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 3241
Study 14960663 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapezial excision with ligament reconstruction (group I)
Number of subjects: 43
Study 14960663 — intervention group
Group type: COMPARATOR
Intervention: Trapezial excision with ligament reconstruction combined with tendon interposition (group II)
Number of subjects: 43
Study 10931767 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone supplementation in older men
Number of subjects: 0
Study 10931767 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen supplementation in older women
Number of subjects: 0
Study 10931767 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone and estrogen effects in men
Number of subjects: 0
Study 9071516 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG ROD implants
Number of subjects: 398
Study 9071516 — intervention group
Group type: COMPARATOR
Intervention: Norplant-2 implants
Number of subjects: 398
Study 9071516 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 398
Study 8444762 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 16
Study 8444762 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate and Desipramine
Number of subjects: 16
Study 2945123 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (75 mg)
Number of subjects: 20
Study 2945123 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine (100 mg)
Number of subjects: 20
Study 2945123 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline (75 mg)
Number of subjects: 20
Study 2945123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30285823 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based education program delivered by teachers
Number of subjects: 1820
Study 30285823 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention before the program)
Number of subjects: 1820